Eden Empire Inc.

CNSX:EDEN Stock Report

Mkt Cap: CA$685.9k

We’ve recently updated our valuation analysis.

Eden Empire Valuation

Is EDEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EDEN?

Other financial metrics that can be useful for relative valuation.

EDEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.8x
Enterprise Value/EBITDA-0.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does EDEN's PS Ratio compare to its peers?

The above table shows the PS ratio for EDEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.2x
SUGR.H SugarBud Craft Growers
0.3xn/aCA$718.6k
HMPS Hempsana Holdings
0.7xn/aCA$723.9k
PULL Pure Extracts Technologies
0.6xn/aCA$1.2m
REZN Hash
1.2xn/aCA$1.4m
EDEN Eden Empire
2.4xn/aCA$685.9k

Price-To-Sales vs Peers: EDEN is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (3.2x).

Price to Earnings Ratio vs Industry

How does EDEN's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a67.4%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a67.4%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: EDEN is expensive based on its Price-To-Sales Ratio (2.4x) compared to the Canadian Pharmaceuticals industry average (1.1x)

Price to Sales Ratio vs Fair Ratio

What is EDEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EDEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate EDEN's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of EDEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EDEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EDEN's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

  • Take a look at our analysis of EDEN's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Eden Empire regulatory filings.
  • Potentially undervalued companies in the Pharmaceuticals & Biotech industry.